title: Development in lipid drugs.
abstract: Lipopeptide lipid moieties induce dendritic cell (DC) internalization and epitopes are recognized by MHC, the major histocompatibility complex. HIV-1 (human immunodeficiency virus type 1) lipopeptide vaccine candidate elicits immune responses, and sustains HIV control after highly active antiretroviral therapy (HAART). Mp- and Dp-MART (anti-melanoma lipopeptides) induce strong CTL (cytolytic T lymphocyte) response. New BGTC, BGDA, TGKC lipoplexes mediate gene delivery, e.g., into mouse pancreatic tumor nodules. Triterpene glycyrrhizic acid (GL) inhibits SARS-CoV (severe acute respiratory syndrome associated coronavirus) replication. Compared to CDV (cidofovir), CDV ether lipid esters have enhanced activity against vaccinia (VV) and cowpox (CV) viruses in vitro. Oral treatment of VV and CV infected mice with CDV ether lipid esters, as effective as i.p. CDV, may be useful against orthopoxvirus infections in humans.
authors.affiliation: Université Denis Diderot (Paris 7), 2 place Jussieu, 75005 Paris, France. jeanine.raulin@wanadoo.fr
authors.forename: J
authors.initials: J
authors.lastname: Raulin
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D000077404:Cidofovir; D015608:Cowpox virus / Q000187:drug effects / Q000254:growth & development; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D003713:Dendritic Cells / Q000187:drug effects* / Q000378:metabolism; D019695:Glycyrrhizic Acid / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D008055:Lipids / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D008285:Major Histocompatibility Complex; D008545:Melanoma / Q000276:immunology / Q000517:prevention & control; D063065:Organophosphonates / Q000494:pharmacology; D018155:Orthopoxvirus / Q000187:drug effects / Q000254:growth & development; D010455:Peptides / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000254:growth & development; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D063065:Organophosphonates; D010455:Peptides; D019695:Glycyrrhizic Acid; D003596:Cytosine; D000077404:Cidofovir